{
  "version": "1.0",
  "schema": "https://entitymap.org/spec/v1.0",
  "publisher": {
    "name": "Cyana Therapeutics",
    "url": "https://cyanatx.com/"
  },
  "narrativeBrief": "https://cyanatx.com/llms.txt",
  "generated": "2026-08-11",
  "profile": "healthcare",
  "verificationStatus": "generator-draft",
  "entities": [
    {
      "entityId": "e_cyana",
      "@type": "Organization",
      "name": "Cyana Therapeutics",
      "description": "Precision immuno-oncology company developing drugs to treat solid tumors.",
      "url": "https://cyanatx.com/",
      "relations": [
        {
          "predicate": "PRODUCED_BY",
          "target": "e_shoshana",
          "targetName": "Shoshana Shendelman"
        }
      ],
      "hasChunks": [
        {
          "chunkId": "c_001",
          "text": "Cyana Therapeutics is a precision immuno-oncology company developing drugs to treat solid tumors. Its lead compound, CY-3132, is a small molecule inhibitor of an enzyme called ENPP1, which is upregulated on the surface of many tumor cells.",
          "sourceUrl": "https://cyanatx.com/",
          "pageTitle": "Cyana Therapeutics | Precision Immuno-Oncology",
          "publisher": "Cyana Therapeutics",
          "retrieved": "2026-08-11",
          "relevanceScore": 1,
          "contentType": "definition"
        },
        {
          "chunkId": "c_002",
          "text": "Cyana's pipeline: CY-3132 (subcutaneous injection), an ENPP1 inhibitor for solid tumors in oncology, is at the IND-enabling stage with Phase 1 planned for 2026. CY-3292 (oral), an ENPP1 inhibitor for rare disease applications, is in lead optimization.",
          "sourceUrl": "https://cyanatx.com/",
          "pageTitle": "Cyana Therapeutics | Precision Immuno-Oncology",
          "publisher": "Cyana Therapeutics",
          "retrieved": "2026-08-11",
          "relevanceScore": 0.95,
          "contentType": "fact"
        }
      ]
    },
    {
      "entityId": "e_shoshana",
      "@type": "Person",
      "name": "Shoshana Shendelman",
      "alternateName": [
        "Dr. Shoshana Shendelman",
        "Shoshana Shendelman, PhD"
      ],
      "description": "Co-Founder and CEO of Cyana Therapeutics; scientist and entrepreneur, founder of several biotech companies.",
      "sameAs": [
        "https://drshendelman.com/about/shoshana-shendelman/",
        "https://shoshanashendelman.com/",
        "https://cyanatx.com/about/dr-shoshana-shendelman",
        "https://www.linkedin.com/in/shoshana-shendelman-phd-8756926/",
        "https://x.com/drshendelman",
        "https://www.youtube.com/@DrShendelman",
        "https://www.facebook.com/shoshanashendelman",
        "https://www.forbes.com/profile/shoshana-shendelman/",
        "https://scholar.google.com/citations?user=CaGnZOUAAAAJ&hl=en",
        "https://www.realclearmarkets.com/authors/shoshana_shendelman/",
        "https://www.foxnews.com/person/s/shoshana-shendelman",
        "https://orcid.org/0000-0002-7016-5295",
        "https://www.researchgate.net/profile/Shoshana-Shendelman",
        "https://www.bloomberg.com/profile/person/21035645",
        "https://www.crunchbase.com/person/shoshana-shendelman-shendelman",
        "https://secretary.columbia.edu/directory/shoshana-shendelman",
        "https://people.equilar.com/bio/person/shoshana-shendelman-columbia-university/27810884",
        "https://wbcollaborative.org/women_leaders_ceo/shoshana-shendelman-ph-d/",
        "https://www.iawfoundation.org/community/shoshana-shendelman/profile/"
      ],
      "relations": [
        {
          "predicate": "AFFILIATED_WITH",
          "target": "e_cyana",
          "targetName": "Cyana Therapeutics"
        }
      ],
      "hasChunks": [
        {
          "chunkId": "c_003",
          "text": "Shoshana Shendelman, PhD is the Co-Founder and CEO of Cyana Therapeutics. She is a scientist and entrepreneur, founder of several biotech companies, and a pioneer in developing drugs for rare and underserved diseases. She previously founded and led a public pharmaceutical company through IPO and multiple financing rounds, with drugs advancing to phase 3 development for rare disease and heart failure indications.",
          "sourceUrl": "https://cyanatx.com/about/dr-shoshana-shendelman",
          "pageTitle": "Shoshana Shendelman, PhD — Co-Founder & CEO, Cyana Therapeutics",
          "publisher": "Cyana Therapeutics",
          "retrieved": "2026-08-11",
          "relevanceScore": 1,
          "contentType": "definition"
        },
        {
          "chunkId": "c_004",
          "text": "Dr. Shendelman holds a PhD from Columbia University Vagelos College of Physicians and Surgeons, plus MA and MSc degrees from Columbia; her doctoral research focused on molecular mechanisms of Parkinson's Disease. She earned a BA in biochemistry from Brandeis University, holds numerous patents, and has published in journals including Orphanet Journal of Rare Diseases and PLoS Biology.",
          "sourceUrl": "https://cyanatx.com/about/dr-shoshana-shendelman",
          "pageTitle": "Shoshana Shendelman, PhD — Co-Founder & CEO, Cyana Therapeutics",
          "publisher": "Cyana Therapeutics",
          "retrieved": "2026-08-11",
          "relevanceScore": 0.9,
          "contentType": "credential"
        }
      ]
    },
    {
      "entityId": "e_jessica",
      "@type": "Person",
      "name": "Jessica Dennison",
      "alternateName": [
        "Jessica Dennison, PhD",
        "Dr. Jessica Dennison"
      ],
      "description": "Chief Operating Officer of Cyana Therapeutics; translational scientist and biotech entrepreneur.",
      "relations": [
        {
          "predicate": "AFFILIATED_WITH",
          "target": "e_cyana",
          "targetName": "Cyana Therapeutics"
        }
      ],
      "hasChunks": [
        {
          "chunkId": "c_005",
          "text": "Dr. Jessica Dennison is a translational scientist and emerging biotech entrepreneur. She serves as Chief Operating Officer of Cyana Therapeutics, where she manages cross-functional teams and external partners, leads business development, and supports fundraising.",
          "sourceUrl": "https://cyanatx.com/about/dr-jessica-dennison",
          "pageTitle": "Jessica Dennison, PhD — COO, Cyana Therapeutics",
          "publisher": "Cyana Therapeutics",
          "retrieved": "2026-08-11",
          "relevanceScore": 0.85,
          "contentType": "definition"
        }
      ]
    }
  ]
}